Selected data models

You must log in to select data models for download or further analysis.

14 Search results.
Relevance Rating New first Old first

dbGaP phs000944 eMERGE Clinical Center at Partners HealthCare - Eligibility

- 11/27/24 - 6 forms, 2 itemgroups, 11 items, 1 language
Itemgroups: IG.elig, IG.elig
Principal Investigator: Scott T. Weiss, MD, MS, Partners HealthCare System, Boston, MA, USA MeSH: Hypercholesterolemia,Asthma,Arthritis, Rheumatoid,Attention Deficit Disorder with Hyperactivity,Bipolar Disorder,Coronary Disease,Depression,Heart Failure,Inflammatory Bowel Diseases,Multiple Sclerosis,Schizophrenia,Stroke https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000944 The Partners HealthCare Biobank is a large research data and sample repository working within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance understanding of the causes of common diseases, and advance the practice of medicine. The Partners Biobank provides banked samples (plasma, serum and DNA) collected from consented patients. These samples are available for distribution to Partners HealthCare investigators with appropriate approval from the Partners Institutional Review board (IRB). They are linked to clinical data that originates in the Electronic Medical Record (EMR), as well as additional health information collected in a self-reported survey. The Partners Biobank will be genotyping 25,000 subjects with the Illumina Multiethnic Beadchip 1.6 million SNPs with exome and custom content ( 60,000 LoFs). Of the participants genotyped so far, 4929 of 4962 (99.3%) individuals have genotype data that passed the default quality thresholds for the Infinium array (call rate = 0.99). We are submitting the genotype data to dbGaP for 4929 subjects with 12 phenotypes (based on icd9 codes). We will do annual releases until we reach the full 25,000 genotyped subjects.

pht004847.v1.p1

1 itemgroup 5 items

pht005288.v1.p1

1 itemgroup 6 items

pht004844.v1.p1

1 itemgroup 2 items

pht004845.v1.p1

1 itemgroup 3 items

pht004846.v1.p1

1 itemgroup 18 items

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Chest X-Ray; Tender Joint Count; Swollen Joint Count; Electronically Transferred Lab Data; ESR

- 3/17/20 - 1 form, 11 itemgroups, 33 items, 1 language
Itemgroups: Chest X-Ray, Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Electronically Transferred Lab Data, ESR - Local Laboratory
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Eligibility Rheumatoid Arthritis NCT01029613

- 10/9/18 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers; ODM derived from: https://clinicaltrials.gov/show/NCT01029613

Eligibility Rheumatoid Arthritis NCT00361634

- 6/17/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00361634

Tocilizumab and non-biological DMARD in Rheumatoid Arthritis NCT01034397 - Eligibility Criteria

- 5/21/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs; ODM derived from: https://clinicaltrials.gov/show/NCT01034397

Eligibility Rheumatoid Arthritis NCT00484809

- 12/13/16 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children; ODM derived from: https://clinicaltrials.gov/show/NCT00484809

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Early Withdrawal - Administrative; Pain Assessment VAS Score; Patient's Global Assessment of Arthritis Condition VAS Score; Physician's Global Assessment of Arthritis Condition VAS Score; Vital Signs; ECG; Neurological Examination

- 3/24/20 - 1 form, 7 itemgroups, 21 items, 1 language
Itemgroups: Administrative, Pain Assessment VAS Score , Patient's Global Assessment of Arthritis Condition VAS Score , Physician's Global Assessment of Arthritis Condition VAS Score, Vital Signs , ECG , Neurological Examination
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Unscheduled - Electronically Transferred Lab Data; ESR; Neurological Examination; Vital Signs; Liver Event Assessment

- 3/24/20 - 1 form, 5 itemgroups, 20 items, 1 language
Itemgroups: Electronically Transferred Lab Data , ESR, Neurological Examination , Vital Signs , Liver Event Assessment
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 9 - Vital Signs; ECG; Neurological Examination

- 3/23/20 - 1 form, 3 itemgroups, 11 items, 1 language
Itemgroups: Vital Signs , ECG, Neurological Examination
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 4; 5; 7; 8; 9 - Vital Signs; Neurological Examination; Tender Joint Count; Swollen Joint Count; Swollen/Tender Joint Count

- 3/23/20 - 1 form, 11 itemgroups, 26 items, 1 language
Itemgroups: Vital Signs , Neurological Examination, Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Swollen/ Tender Joint Count
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 6 - Vital Signs; Neurological Examination; Tender Joint Count; Swollen Joint Count; Swollen/Tender Joint Count

- 3/23/20 - 1 form, 11 itemgroups, 27 items, 1 language
Itemgroups: Vital Signs , Neurological Examination, Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Swollen/ Tender Joint Count
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Vital Signs; Medical Conditions; Eligibility Question; Neurological Examination; ECG

- 3/17/20 - 1 form, 5 itemgroups, 12 items, 1 language
Itemgroups: Vital Signs, Medical Conditions, Eligibility Question, Neurologic Examination, ECG
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial